hVIVO plc
HVO:LN
Latest Coverage
Overview
Company Profile
(Ticker: HVO) is a full-service early phase Contract Research Organisation (CRO) and the global leader in human challenge trials. The Company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world’s ten largest biopharma companies.
hVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in London—the largest of its kind worldwide. The Company also offers comprehensive virology and immunology laboratory services under the hLAB brand.
Through its German subsidiary, CRS, hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. Its second subsidiary, Venn Life Sciences, offers Early Drug Development Consulting and Biometry services to the biopharma sector.
The Group provides fully integrated drug development solutions from preclinical stages through Phase II trials, alongside patient recruitment via FluCamp. Additionally, its five clinical sites support outpatient Phase II and III trials, ensuring a seamless and efficient pathway from discovery to late-stage development.
Sep 23, 2025
Jul 22, 2025
Apr 15, 2025
Apr 11, 2025
Apr 10, 2025
Feb 18, 2025
Jan 29, 2025
Jan 27, 2025
Jan 21, 2025
Jan 21, 2025
Classification
Financials
News & Media
Corporate
Board of Directors
Stephen Pinkerton
Chief Financial Officer
Stephen is a chartered accountant with over 25 years of experience in a range of leadership positions in industries covering publishing, technology, exhibitions, and clinical research. The roles have covered both small to large international listed businesses, providing strong technical and commercial experience. Prior to joining hVIVO, he worked in Thomson Reuters for eleven years in various senior roles. He did his articles with Deloitte following the completion of an Honours Degree in Bachelor of Commerce and a Bachelor’s Degree in Accounting and Finance from the University of Cape Town.
Professor Brendan Buckley
Non-Executive Director
Prof. Brendan Buckley is a medical graduate of University College Cork and a doctoral graduate of Oxford University . For most of his career he worked in academic clinical practice as a consultant physician. He holds professorial titles in the faculties of Medicine at Universities in Cork and Dublin. He has over 30 years’ experience in clinical research in roles as chief investigator, chair of data and safety monitoring committees and on institutional review boards. He became Chief Medical Officer of ICON plc, following their acquisition of Firecrest Clinical Ltd, which he had co-founded. He was a member of ICON plc’s Executive Leadership Team and was actively involved in M&A targeting, assessment and diligence. Firecrest was one of a number of companies focused on clinical trial innovation which he co-founded and sold. Brendan was a non-executive director of the Irish national medicines regulatory authority (now the Health Products Regulatory Authority) between 2004 and 2011. He was a member of the inaugural European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) and of the EMA Scientific Advisory Group for Diabetes and Endocrinology as well as teaching on FDA advanced courses on clinical trials. He serves on the boards of various pharma development and services companies, some of which he has co-founded. Brendan has over 150 scientific publications, including the key opinion-leading book ‘Re-Engineering Clinical Trials’.
Elaine Sullivan
Senior Independent Non-Executive Director
Dr Elaine Sullivan is a Senior pharmaceutical and biotech industry executive with a successful track record in science, investment, business development, and start-ups with over 25 years’ experience. She has extensive global leadership experience including membership of the top senior global R&D management teams at Eli Lilly (US) where she held the position of Vice President Global External Research & Development, and she was a member of Lilly Ventures and Lilly Asian Venture steering Committee. At AstraZeneca (UK) she held a number of positions including Vice President R&D, Head of New Opportunities Therapy Area and Vice President, Science & Technology. Former positions also include positions co-founder and CEO of Carrick Therapeutics. Her board appointments include Member of the Supervisory Board of Evotec AG, Non-Executive Director of the IP Group plc, hVIVO plc, Zealand Pharmaceuticals and Nykode Therapeutics ASI where she is also the Chair of the R&D committee. In addition, Elaine is a member of the Scientific Advisory board of Poolbeg Pharma. She was named Ernst Young Emerging Entrepreneur of the Year (Ireland) Executed external risk share partnerships, to access to global innovation while balancing scientific and financial risk. member of the steering and investment boards of Capital Funds, Lilly Ventures, and Lilly Asian Ventures. Former positions include Co-founder and CEO of Carrick Therapeutics raised $95 million Series A. Vice-President R&D, Head of New Opportunities Therapy Area (AstraZeneca, UK), creating additional value from the AstraZeneca portfolio by repositioning molecules to other diseases and entering new therapy areas/diseases via spinouts, joint ventures, strategic partnerships, and acquisitions. Delivered over 250 collaborations and transactions including spinouts, joint ventures, strategic partnerships and multi-million US$ acquisitions. Extensive experience in executing deals world-wide including US, Europe, and China. Worked globally in US and Europe. Winner of the Ernst Young Emerging Entrepreneur of the Year (Ireland).
Shaun Chilton
Non-Executive Chair
Shaun brings substantial sector-relevant experience and expertise to the Board, underpinned by a track record of delivering strong growth in sales and enterprise value. He brings over 30 years of experience leading and managing both private and public businesses. Shaun was previously Chief Executive Officer of Clinigen Group plc, a global pharmaceutical services group operating in more than 100 countries and has considerable board experience within UK public companies. He is currently Non-Executive Chair of Avacta Group plc, Non-Executive Chair of Kintiga Limited, and Independent Supervisory Board Member of Product Life Group.
Yamin ‘Mo’ Khan
Chief Executive Officer
Mo is CEO of hVIVO with over 25 years of experience in clinical research and the CRO industry. Mo has worked as a consultant assisting CROs to develop growth strategies and helping prepare companies for future expansion, both organic and through M&A activity. In addition, Mo worked with Private Equity firms providing insight in identifying potential targets and conducting due diligence in preparation for M&A activity. Prior to this Mo had a variety of senior roles at Pharm-Olam where he played a pivotal role in growing a small niche clinical monitoring business to a global full-service CRO with offices across all continents. In his time at Pharm-Olam Mo had leading roles in Clinical Operations, Project Management, Business Development and Executive Management functions. As a key member of the Executive Team Mo participated in the successful sale of the company in 2017, delivering substantial returns to its shareholders. Prior to this he worked at Innovex and Quintiles (IQVIA).